We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions.
By leveraging our expansive knowledge of the melanocortin system, we design our therapeutics to directly engage one of the body’s natural pathways to resolve harmful inflammation, providing a unique approach that allows affected tissue time to heal.
Palatin Technologies Inc. (PTN)
|Volume||60,499||52 Week Range||1.59-1.91|
Information for Investors
Portions of this website contain forward-looking statements that are subject to change. Statements about future expectations of Palatin Technologies, Inc., including statements about our marketed products, development programs, proposed indications for our product candidates, preclinical activities, marketing collaborations, and all other statements in this document other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for various reasons, including but not limited to our ability to fund development of our technology, our ability to establish and successfully complete clinical trials and preclinical studies, and the results of those trials and studies, dependence on our partners for certain development activities, need for regulatory approvals and commercial acceptance of our products, our ability to protect our intellectual property, adoption of new accounting regulations and standards, adverse changes in the securities markets, our ability to comply with continued listing requirements of the NYSE American stock exchange, and other factors discussed in our periodic filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, our Quarterly Reports, and other periodic reports. We do not undertake, and specifically disclaim any obligation, to release publicly the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.